Blog Posts
March 29, 2021

Zoom In: 10 Tips to Make Virtual KOL Meetings more Engaging and Productive

Blog Posts
March 29, 2021

Zoom In: 10 Tips to Make Virtual KOL Meetings more Engaging and Productive

Author

Read this article first published on The MSL Journal to uncover tips that will help you maintain and even strengthen your relationships with KOLs with engaging virtual meetings.

Medical Science Liaisons have been especially impacted by COVID-19 restrictions on in-person meetings. Most have shifted to connecting with KOLs virtually using videoconferencing solutions like Zoom, Microsoft Teams, or Google Meet. Though definitely a change in the day-to-day life of any MSL, this transition has been relatively smooth.

A  survey of 245 KOLs by the Medical Science Liaison Society (MSLS) found that:

  • MSLs are still getting meetings. In fact, 50% of MSLs surveyed were able to maintain an average of 1-3 virtual visits per month, just slightly lower than the 63% who met this goal in-person before the pandemic.
  • And they are successful meetings. 78% rated the effectiveness of virtual discussion with MSLs as either “somewhat” or “very” effective during this time.

Another survey of MSLs which we partnered with MSLS to conduct showed that:

  • 10% of MSLs were able to increase their KOL engagements since the pandemic began.
  • And despite an overall decrease in engagements, MSLs reported that the quality of their relationships with KOLs improved.

This is encouraging news as virtual meetings are definitely a part of the future of KOL engagement. Whatever the post-COVID landscape looks like, MSLs will likely adopt a hybrid model–mixing in-person and virtual meetings for greater convenience and productivity.

We say this is encouraging because we believe this shift can strengthen the connection between MSLs and KOLs. As a global, remote-first team, we’ve learned firsthand how to make the most of video as a platform for getting business done and building real connections. With lots of practice, our team has discovered ways to make our time on video (and increasingly now in virtual reality) both meaningful and effective.

Zoom-in10-tips-to-make-Virtual-KOL-meetings-more-Engaging-and-productive

Here are 10 tips from our experience in the video meeting world. These best practices can help strengthen your virtual meeting skills and maximize the efficiency of your meetings with KOLs.

10 Tips for Virtual KOL Meeting Success

  1. Set the Proper Mood – No one expects these meetings to be professionally produced, but you do still want to set yourself up for success. Pay attention to lighting, camera placement, and audio. Try to sit facing natural light, and never have bright lights behind you, which make you look dark. If you don’t have windows, put small lamps behind both sides of the computer angled toward your face. Since the camera is typically at the top of the laptop, tablet, or phone, angle the screen so its top aligns with your eyes, or put a few books under your device to bring it to eye level.
  2. Dress for Success – Looking professional on a video call requires specific attention to wardrobe, at least on your top half. Shirts with bright, solid colors show up well on camera. Most video platforms also have a way to “touch up your appearance” in the video settings menu. That’s a helpful confidence boost, but don’t get carried away. Authenticity is key, and the opposite is easy to read on video.

Continue reading at The MSL Journal here.

Download attached file
Not rated
Allison Betof Warner, MD, PhD (she/her) 4
3743
Manhattan, NY
November 10, 2022

79% had reduction in disease. ORR 31%. Many responses deepen over time.

Not rated
Allison Betof Warner, MD, PhD (she/her) 3
3743
Manhattan, NY
November 10, 2022

Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

Positive
Alex Shoushtari, MD
2253
New York, USA
November 10, 2022

Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

Not rated
Allison Betof Warner, MD, PhD (she/her) 2
3743
Manhattan, NY
November 10, 2022

Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

Positive
Hussein Tawbi, MD, PhD
1685
Houston, TX
November 10, 2022

Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

Positive
Allison Betof Warner, MD, PhD (she/her) 1
3744
Manhattan, NY
November 10, 2022

Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

Not Rated
Sumanta K. Pal, MD, FASCO
15083 Followers
Los Angeles, CA
November 8, 2022

Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

not rated
Shilpa Gupta
5095 Followers
Cleveland, OH
November 8, 2022
Not Rated
Tian Zhang, MD, MHS
6463 Followers
Dallas, TX
November 8, 2022

CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

Not Rated
Moshe Ornstein MD
1930 Followers
Cleveland, OH
November 8, 2022

Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

Not Rated
Shuchi Gulati MD
12476 Followers
Seattle, WA
November 8, 2022

Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

Not Rated
Petros Grivas
12476 Followers
Seattle, WA
November 8, 2022

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.